What is TRVI's current stock price?

TRVI (Trevi Therapeutics, Inc.) is currently trading at $14.13 with a market cap of $2.01B.

What sector is Trevi Therapeutics, Inc. in?

Trevi Therapeutics, Inc. (TRVI) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is TRVI a good stock to buy?

Analysts have a Buy consensus on TRVI with a price target of $25.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

TRVI Trevi Therapeutics, Inc.

Healthcare

$14.13-0.21%ClosedMarket Cap: $2.01B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

11.95

P/S

0.00

EV/EBITDA

-42.04

DCF Value

$0.11

FCF Yield

-1.6%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-24.5%

ROA

-25.4%

ROIC

-30.5%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-13.2M	$—
Q4 null	$0.00	$-8.3M	$—
FY null	$0.00	$-42.8M	$—
Q3 null	$0.00	$-11.8M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$25.00

Target (Median)

$25.00

Target Range

$20.00 - $30.00

2 Strong Buy9 Buy0 Hold0 Sell0 Strong Sell

NeedhamBuy

2026-05-20

HC Wainwright & Co.Buy

2026-05-06

D. Boral CapitalBuy

2026-04-17

Jones TradingBuy

2026-03-19

NeedhamBuy

2026-03-18

Trading Activity

Insider Trades

View All

Simon Farrellofficer: Chief Commercial Officer

SellFri Feb 20

SCIASCIA THOMASofficer: Chief Scientific Officer

SellFri Feb 20

GOOD JENNIFER Ldirector, officer: President & CEO

SellFri Feb 20

Galletta Christopherofficer: See Remarks

SellFri Feb 20

Cassella James Vofficer: Chief Development Officer

SellFri Feb 20

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.08

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Peers

UPB

WVE

ZBIO

ZYME